Ohio VC: BioSynth Dynamics’ 2026 Funding Fight

Listen to this article · 10 min listen

In 2026, Sarah Chen had a breakthrough and a big problem. As CEO of BioSynth Dynamics, her Columbus-based team had nailed a new method for targeted drug delivery, but their seed money was almost gone. She needed a Series A round, a big one, and trying to raise it in Ohio felt like fighting with one hand tied behind her back. The old perception was sticking: Ohio’s for manufacturing, and if you’re a deep tech play needing serious early cash, you’d better be looking at the coasts. Could BioSynth, with real science in hand, actually get the funding it needed to go from a lab concept to a market-ready therapy inside the Ohio VC world?

Key Takeaways

  • VC money in Ohio hit $3.1 billion over 250 deals in 2025, a 15% jump from the year before.
  • VCs want to see you have ties to the big local players, think Procter & Gamble or Marathon Petroleum.
  • The Ohio Innovation Fund, backed by major institutions, is actively hunting for Series A and B deals in advanced manufacturing and life sciences.
  • To get a check over $5 million, your pitch needs rock-solid IP protection and a believable go-to-market plan.
  • Regional angel networks and university tech transfer offices are your best bet for the pre-seed and seed money that gets you to the bigger VC rounds.

The Initial Hurdle: Perception Versus Reality in Ohio’s Startup Ecosystem

Sarah’s struggle wasn’t new. For a lot of Midwest founders, there’s a gap between the tech they’re building and what investors on the outside see. Ohio has amazing research hubs at Ohio State University and Case Western Reserve, but turning that R&D into a VC-backed company has always been a slower grind here than in Boston or Silicon Valley. “We had the science, patents, and a clear runway to preclinical trials,” Sarah told me at a Columbus tech event. “But the first question from every West Coast VC was, ‘Are you willing to move?’ It was infuriating.” That geographical bias is still a real factor, and anyone raising money in the startup ecosystem knows it’s not disappearing overnight.

If you look at the National Venture Capital Association’s annual report, the numbers tell the story. Total VC investment in Ohio climbed to about $3.1 billion across 250 deals in 2025, which is a healthy increase, but it’s still just a tiny piece of the pie compared to California or New York. The data shows a market that’s growing up, but isn’t quite there yet. Deal sizes in Ohio are also smaller on average, with most of the action happening at the seed stage. BioSynth Dynamics was looking for a $10 million Series A, not a crazy number, but one that put them into a much tougher, more competitive fight for the attention of Ohio-based funds.

Building Local Connections: The First Step Towards Funding

After banging her head against the wall with out-of-state investors, Sarah switched gears and focused on her own backyard. Her first move was to start showing up at everything hosted by Rev1 Ventures, the Columbus-based investor that’s a known hub for startups. “The point wasn’t just to pitch everyone I met,” she explained. “It was about learning the local investment thesis, figuring out who the real players were, and what metrics they actually cared about.” She had to re-tool her entire deck to speak directly to Ohio’s focus on advanced manufacturing, healthcare IT, and the specific kind of biotech they understood.

A mentor from Rev1 made the connection that changed things, introducing her to an angel investor down in Cincinnati with deep roots in the pharma industry. He wasn’t the right fit for the Series A check, but he gave her brutally honest feedback on BioSynth’s commercialization plan and made the critical introduction to partners at the Ohio Innovation Fund (OIF). Headquartered in Columbus, OIF has become a serious force, often co-investing with bigger national VCs but always with a mandate to fund Ohio companies. Their portfolio was full of advanced materials and digital health companies, plus some specialized life sciences, which put BioSynth right in their sweet spot.

The Ohio Innovation Fund: A Deeper Dive into Local Investment Thesis

With over $150 million under management, the Ohio Innovation Fund is a huge part of the funding equation for companies like BioSynth. Their thesis is simple: they want companies with defensible IP, some sign of market traction (no matter how early), and a plan to scale up in Ohio. A senior partner at OIF put it bluntly during a panel in Cleveland: “We don’t fund ideas, we fund companies. Show us you have a team that knows how to build a business, not just a cool product. And honestly, we want teams who are committed to growing here.”

Sarah quickly learned that OIF cared a lot about customer validation and who she was talking to for strategic partnerships. For BioSynth, that meant she had to go beyond showing that her drug delivery platform worked. She had to line up potential deals with big pharma companies or research institutions. She spent months working to get a letter of intent from a major Cleveland research hospital to run the first human trials. It was a miserable process of endless meetings and working through hospital bureaucracy, but it was the one piece of paper that proved someone outside her own lab believed in the technology. That turned out to be the key.

Beyond the Pitch Deck: Demonstrating Market Readiness and Team Strength

The due diligence process with OIF was a beast. It went way past the pitch deck. They picked apart BioSynth’s patent portfolio, interviewed her key scientists, and hired their own consultants to double-check her market analysis for oncology. “They looked at our financials, sure, but they also dug into our hiring plan, our entire regulatory strategy, and how we’d handle risk,” Sarah recounted. “It felt like they were stress-testing every single part of the business.”

A recurring theme with successful Ohio VC pitches is the focus on the team. Local investors, maybe more than those in saturated coastal markets, bet on resilience and the ability to execute. BioSynth’s team was a mix of hardcore scientists and a COO who’d been through the biotech startup wringer before. Sarah’s own background, a PhD in biochemistry combined with R&D experience at a major pharma company, gave investors confidence she could handle the business side, not just the lab work. They want to know that when a crisis hits, and it always does, the leadership can navigate it.

I find too many founders just list impressive resumes on a slide. You have to explain how your team works under pressure and how you resolve conflict. It’s that human dynamic that can make or break a deal when all the spreadsheets start to look the same. A strong team figures out how to pivot and learn from mistakes. A weak one shatters at the first real problem.

The Role of University Tech Transfer and Corporate Partnerships

So much of the Ohio startup ecosystem gets its start inside a university lab. The tech commercialization offices at places like the University of Cincinnati and The Ohio State University are actively trying to spin out research. BioSynth itself was born from research at OSU, and Sarah kept those ties strong. The tech transfer office helped with IP licensing and even pointed her toward grants that kept the lights on between the early lab work and her first seed checks.

You also have to remember that Ohio’s big corporations are hungry for innovation and are starting to look in their own backyard. A Procter & Gamble in Cincinnati, Marathon Petroleum in Findlay, or Goodyear in Akron isn’t just a potential customer. They can be a strategic investor or your first pilot partner. Even though BioSynth’s work wasn’t for consumer goods, Sarah was smart enough to brainstorm how her tech could apply to veterinary medicine, a space where some of those big players have side interests. Thinking three steps ahead about tangential markets and potential corporate allies is exactly the kind of commercialization mindset investors want to see.

Securing the Series A: Proof of Persistence and Local Strategy

It took almost eight months of grinding, non-stop meetings, due diligence, and constant refining of the business plan, but BioSynth Dynamics finally closed its $10 million Series A. The Ohio Innovation Fund led the round, and they brought in a national life sciences VC firm they had worked with before. That co-investment was the real prize. It gave BioSynth validation from a national player and access to a wider network, all while keeping the company’s center of gravity in Ohio.

“It wasn’t just the money,” Sarah said. “We found partners who got the vision and who also understood the advantages of building a biotech company right here. The support from the state, the talent coming out of the universities, and the investor confidence, it’s all real.” Now they have the cash to push forward on preclinical trials, hire more researchers, and start the long process of FDA applications. Her whole journey is a masterclass for any founder in the region: forget the glamour of a national profile if you haven’t first locked down your own backyard. The fastest path to a term sheet is often right here in the Ohio VC field.

Conclusion

If you want to raise VC money in Ohio, you have to do the work. That means getting deeply plugged into the local networks, tailoring your story for what regional funds actually invest in, and proving you’re ready to execute from day one. For any startup trying to land a big round, showing your team can deliver results and knowing how to use the state’s corporate and university support system is everything.

What is the average venture capital deal size in Ohio?

Deal sizes are typically smaller than on the coasts, so you see a lot more seed and early-stage rounds. That said, Series A and B rounds are getting bigger and more frequent as the market matures.

Which sectors attract the most venture capital in Ohio?

The money tends to follow the state’s strengths. You’ll see a lot of investment in advanced manufacturing, life sciences like biotech and medtech, plus healthcare IT and other specialized software.

How can Ohio startups connect with local investors?

Get out there. Go to events put on by groups like Rev1 Ventures in Columbus or JumpStart Inc. in Cleveland. Get involved with your local university’s tech transfer office and start networking through your industry’s associations. The Ohio Innovation Fund also hosts events.

Are there specific funds focused on Ohio-based companies?

Absolutely. Funds like the Ohio Innovation Fund and Drive Capital exist specifically to back Ohio startups, and you also have accelerator-affiliated funds like Rev1 Ventures that are deeply focused on the local scene.

What do Ohio venture capitalists prioritize in a pitch?

They want to see a few key things: strong, defensible IP is a must. They’ll scrutinize your team’s experience and grit. You also need some kind of market validation, a business model that can actually scale, and a real commitment to building the company in Ohio.

Editorial Team

The Editorial Team at The Founders Space is a group of writers and editors who cover the stories shaping their industry. They research each story and publish under a shared desk byline — experts in their fields, working as one team.